Relaxin does not improve Angiotensin II-induced target-organ damage.

Relaxin is a corpus-luteum produced protein hormone with vasodilatatory, anti-fibrotic, and angiogenic properties that are opposite to angiotensin (Ang) II. We investigated whether or not relaxin ameliorates Ang II-induced target-organ damage. We used double transgenic rats harboring both human reni...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nadine Haase, Julianna Rugor, Lukasz Przybyl, Fatimunnisa Qadri, Dominik N Müller, Ralf Dechend
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ed96280a03b74b10bf01a59306c3446f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ed96280a03b74b10bf01a59306c3446f
record_format	dspace
spelling	oai:doaj.org-article:ed96280a03b74b10bf01a59306c3446f2021-11-18T08:24:38ZRelaxin does not improve Angiotensin II-induced target-organ damage.1932-620310.1371/journal.pone.0093743https://doaj.org/article/ed96280a03b74b10bf01a59306c3446f2014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24710077/?tool=EBIhttps://doaj.org/toc/1932-6203Relaxin is a corpus-luteum produced protein hormone with vasodilatatory, anti-fibrotic, and angiogenic properties that are opposite to angiotensin (Ang) II. We investigated whether or not relaxin ameliorates Ang II-induced target-organ damage. We used double transgenic rats harboring both human renin and angiotensinogen genes (dTGR) that develop severe hypertension, target-organ damage, and die untreated within 7-8 weeks. Recombinant relaxin at a low (26 μg/kg/d) and a high dose (240 μg/kg/d) was given to 4 week-old dTGR and age-matched Sprague-Dawley rats (SD). Systolic blood pressure increased progressively in untreated dTGRs from 162 ± 3 mmHg at week 5 to 225 ± 5 mmHg at week 7. Relaxin had no effect on blood pressure whereas SD rats were normotensive (106 ± 1 mmHg). Untreated and relaxin-treated dTGR had similarly severe cardiac hypertrophy indices. Relaxin did not ameliorate albuminuria and did not prevent matrix-protein deposition in the heart and kidney in dTGR. Finally, relaxin treatment did not reduce mortality. These data suggest that pharmacological doses of relaxin do not reverse severe effects of Ang II.Nadine HaaseJulianna RugorLukasz PrzybylFatimunnisa QadriDominik N MüllerRalf DechendPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 4, p e93743 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Nadine Haase Julianna Rugor Lukasz Przybyl Fatimunnisa Qadri Dominik N Müller Ralf Dechend Relaxin does not improve Angiotensin II-induced target-organ damage.
description	Relaxin is a corpus-luteum produced protein hormone with vasodilatatory, anti-fibrotic, and angiogenic properties that are opposite to angiotensin (Ang) II. We investigated whether or not relaxin ameliorates Ang II-induced target-organ damage. We used double transgenic rats harboring both human renin and angiotensinogen genes (dTGR) that develop severe hypertension, target-organ damage, and die untreated within 7-8 weeks. Recombinant relaxin at a low (26 μg/kg/d) and a high dose (240 μg/kg/d) was given to 4 week-old dTGR and age-matched Sprague-Dawley rats (SD). Systolic blood pressure increased progressively in untreated dTGRs from 162 ± 3 mmHg at week 5 to 225 ± 5 mmHg at week 7. Relaxin had no effect on blood pressure whereas SD rats were normotensive (106 ± 1 mmHg). Untreated and relaxin-treated dTGR had similarly severe cardiac hypertrophy indices. Relaxin did not ameliorate albuminuria and did not prevent matrix-protein deposition in the heart and kidney in dTGR. Finally, relaxin treatment did not reduce mortality. These data suggest that pharmacological doses of relaxin do not reverse severe effects of Ang II.
format	article
author	Nadine Haase Julianna Rugor Lukasz Przybyl Fatimunnisa Qadri Dominik N Müller Ralf Dechend
author_facet	Nadine Haase Julianna Rugor Lukasz Przybyl Fatimunnisa Qadri Dominik N Müller Ralf Dechend
author_sort	Nadine Haase
title	Relaxin does not improve Angiotensin II-induced target-organ damage.
title_short	Relaxin does not improve Angiotensin II-induced target-organ damage.
title_full	Relaxin does not improve Angiotensin II-induced target-organ damage.
title_fullStr	Relaxin does not improve Angiotensin II-induced target-organ damage.
title_full_unstemmed	Relaxin does not improve Angiotensin II-induced target-organ damage.
title_sort	relaxin does not improve angiotensin ii-induced target-organ damage.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/ed96280a03b74b10bf01a59306c3446f
work_keys_str_mv	AT nadinehaase relaxindoesnotimproveangiotensiniiinducedtargetorgandamage AT juliannarugor relaxindoesnotimproveangiotensiniiinducedtargetorgandamage AT lukaszprzybyl relaxindoesnotimproveangiotensiniiinducedtargetorgandamage AT fatimunnisaqadri relaxindoesnotimproveangiotensiniiinducedtargetorgandamage AT dominiknmuller relaxindoesnotimproveangiotensiniiinducedtargetorgandamage AT ralfdechend relaxindoesnotimproveangiotensiniiinducedtargetorgandamage
_version_	1718421834759667712

Relaxin does not improve Angiotensin II-induced target-organ damage.

Ejemplares similares